default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Yuhan markets high-dose copy of Agrylin

Lee Hye-seon  Published 2018.09.14  13:42  Updated 2018.09.14 13:42

공유
default_news_ad2

Yuhan Corp. is to roll out a high-dose generic drug of Agrylin Cap. (ingredient: anagrelide) soon, after returning sales rights of Shire’s original drug. Yuhan’s generic copy is a second of its kind, with the first marketed by Pharmbio Korea.

The Ministry of Food and Drug Safety on Thursday approved Yuhan to distribute Anagre Cap. 1mg for treating thrombocytosis from myeloproliferative disorder, a rare, intractable disease. The drug reduces elevated platelet levels, the risk of thrombosis, and thrombotic-bleeding tendencies.

The effect of platelet reduction is related to the drug dose. A high-dose treatment can quickly lower platelet counts. Pharmbio Korea recently obtained the nod for a high-dose 1mg product.

Yuhan and Pharmbio Korea aim to meet the needs of patients who want a faster reduction of platelets with high-dose therapies.

Yuhan started selling Shire’s Agrylin in 1988 but returned its sales rights in 2016 due to Shire’s entry into the local market.

Also in 2016, Yuhan won approval for Anagre Cap. 0.5mg, a generic drug of Agrylin.

lhs@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch